|
|
Strategic Navigators

Ulcerative Colitis Competitive Landscape

Pages: 93
Published: August 2022
Individual License: $4,950
Team License: $5,950
ulcerative colitis drugs, ulcerative colitis medications, biologics for ulcerative colitis, UC treatment, ulcerative colitis market research

Ulcerative Colitis Competitive Landscape details the current state of ulcerative colitis drug brands and the impact of future market entrants. Between cutting edge biologics and traditional, baseline treatments, gastroenterologists have a wide range of options when it comes to prescribing ulcerative colitis drugs.

As newly launched brands and pipeline treatments try to navigate the ulcerative colitis market, it’s helpful to understand potential competitors and opportunities to help your brand stand out to HCPs. The competitive landscape for the different ulcerative colitis drugs is unique to each brand. Therefore, each manufacturer will target a different aspect of its UC treatment, but there will also be some similarities between ulcerative colitis drugs.

The UC landscape has many traits that must be considered for a brand to thrive, such as competitors, pipeline products, and brand perceptions.  This report illustrates each part of the current and future landscape of the ulcerative colitis market in order to give a proper perspective. Moreover, with a thorough patient share breakdown by brand, this report is a valuable tool to inform your ulcerative colitis drug’s launch strategy, marketing plan or communications playbook. 

Overview of Ulcerative Colitis Drugs

The ulcerative colitis market has many big-name competitors with various traits. Ulcerative Colitis Competitive Landscape is an in depth look at these major players in the market, showcasing ulcerative colitis drugs’ strengths and weaknesses. These pipeline insights will guide companies on how to best approach the UC marketplace.

This report focuses on the ulcerative colitis market and its

  • Current market positions
  • Branded ulcerative colitis drugs
  • Competitors and expectations
  • Pipeline products
  • Patient share per product
  • Expected usage in the next year
  • Prescription patterns
The report covers the following top ulcerative colitis drugs:
  • Humira
  • Entyvio
  • Remicade
  • Stelara
  • Uceris
  • Xeljanz
  • Zeposia
  • Simponi
The report also includes analysis of the following ulcerative colitis pipeline drugs:
  • Upadacitinib
  • Etrasimod
  • Filgotinib
  • Risankizumab
  • Mirikizumab
  • Guselkumab
  • Brazikumab
  • Cobitolimod

Strategic Questions Answered about Ulcerative Colitis Drugs and the Competitive Landscape

 
  • Market Positions: Which ulcerative colitis drugs are Rising Leaders, Established Leaders, Falling Leaders, Rising Challengers, Stable Laggards and Outsiders?
  • Competitive Set: Who are the top 2 – 3 competitors for each of the top brands among all ulcerative colitis drugs?
  • Prescription Trends: Which ulcerative colitis medications do physicians expect to prescribe more vs. less over the next 12-months?
  • Pipeline Impact: Which ulcerative colitis drugs will be most impacted in the future by treatments currently in development?

Summary of Strategic Insights about the Ulcerative Colitis Competitive Landscape Report

  • As the most established biologic UC treatment, Remicade continues to have a large patient share and Gastroenterologists anticipate Rx volume to stay the same. Humira is Remicade’s most significant competitor.
  • Xeljanz’ safety and tolerability make it a less than ideal treatment option for Gastroenterologists. Prescription volume will likely stay the same whereas top competitor Zeposia will see a sharp increase.
  • Entyvio has the largest average patient share among branded UC treatments and Gastroenterologists expect prescription volume to continue to increase. Stelara is the strongest competitor to Entyvio.

Benefits of Purchasing the Ulcerative Colitis Competitive Landscape Report

 
  • Cost-efficient insights about ulcerative colitis drugs and manufacturers in the UC market to support your strategic marketing decisions.
  • Insights drawn from in-depth interviews among global KOLs and surveys of more than 125 gastroenterologists
  • A complimentary 30-minute workshop with you (and your team)
  • Unlimited support from Vivisum’s ulcerative colitis strategist for 1-year.

Table of Contents

Executive Summary – 6
  • Research Methodology: Robust Insights from US Gastroenterologists – 7
  • The Strategic Six: Key Insights about the UC Competitive Landscape – 8
  • Market positions – 9
  • Competitors: Current Products – 10
  • Competitors: Pipeline Products – 11
UC Competitive Landscape – 12
  • Patient Share per Product – 13
  • Increased Usage Expected in the Next Year – 14
  • Decreased Usage Expected in the Next Year – 15
  • Stable Rx Patterns – 16
UC Competitor Brand Profiles – 17
  • Humira Top Brand Competitors – 18
    • Humira Top Competitors – 19
    • Humira Brand Competitor Prescribing Patterns – 20
    • Humira Brand Competitor Rational Perceptions – 21
    • Humira Competitor Emotional Brand Personalities – 22
    • Humira Brand Competitor Prescribing Patterns – 23
  • Entyvio Top Brand Competitors – 24
    • Entyvio Top Competitors – 25
    • Entyvio Brand Competitor Prescribing Patterns – 26
    • Entyvio Brand Competitor Rational Perceptions – 27
    • Entyvio Competitor Emotional Brand Personalities – 28
    • Entyvio Brand Competitor Prescribing Patterns – 29
  • Remicade Top Brand Competitors – 30
    • Remicade Top Competitors – 31
    • Remicade Brand Competitor Prescribing Patterns – 32
    • Remicade Brand Competitor Rational Perceptions – 33
    • Remicade Competitor Emotional Brand Personalities – 34
    • Remicade Brand Competitor Prescribing Patterns – 35
  • Stelara Top Brand Competitors – 36
    • Stelara Top Competitors – 37
      Stelara Brand Competitor Prescribing Patterns – 38
    • Stelara Brand Competitor Rational Perceptions – 39
    • Stelara Competitor Emotional Brand Personalities – 40
    • Stelara Brand Competitor Prescribing Patterns – 41
  • Uceris Top Brand Competitors – 42
    • Uceris Top Competitors – 43
    • Uceris Brand Competitor Prescribing Patterns – 44
    • Uceris Brand Competitor Rational Perceptions – 45
    • Uceris Competitor Emotional Brand Personalities – 46
    • Uceris Brand Competitor Prescribing Patterns – 47
  • Xeljanz Top Brand Competitors – 48
    • Xeljanz Top Competitors – 49
    • Xeljanz Brand Competitor Prescribing Patterns – 50
    • Xeljanz Brand Competitor Rational Perceptions – 51
    • Xeljanz Competitor Emotional Brand Personalities – 52
    • Xeljanz Brand Competitor Prescribing Patterns – 53
  • Zeposia Top Brand Competitors – 54
    • Zeposia Top Competitors – 55
    • Zeposia Brand Competitor Prescribing Patterns – 56
    • Zeposia Brand Competitor Rational Perceptions – 57
    • Zeposia Competitor Emotional Brand Personalities – 58
    • Zeposia Brand Competitor Prescribing Patterns – 59
  • Simponi Top Brand Competitors – 60
    • Simponi Top Competitors – 61
    • Simponi Brand Competitor Prescribing Patterns – 62
    • Simponi Brand Competitor Rational Perceptions – 63
    • Simponi Competitor Emotional Brand Personalities – 64
    • Simponi Brand Competitor Prescribing Patterns – 65
Pipeline Competitors – 66
Pipeline Product Familiarity – 67
  • Upadacitinib Competitors and Expectations – 68
    • Upadacitinib Top Competitors – 69
    • Upadacitinib Expectations – 70
  • Etrasimod Competitors and Expectations – 71
    • Etrasimod Top Competitors – 72
    • Etrasimod Expectations – 73
  • Filgotinib Competitors and Expectations – 74
    • Filgotinib Top Competitors – 75
    • Filgotinib Expectations – 76
  • Risankizumab Competitors and Expectations – 77
    • Risankizumab Top Competitors – 78
    • Risankizumab Expectations – 79
  • Mirikizumab Competitors and Expectations – 80
    • Mirikizumab Top Competitors – 81
    • Mirikizumab Expectations – 82
  • Guselkumab Competitors and Expectations – 83
    • Guselkumab Top Competitors – 84
    • Guselkumab Expectations – 85
  • Brazikumab Competitors and Expectations – 86
    • Brazikumab Top Competitors – 87
    • Brazikumab Expectations – 88
  • Cobitolimod Competitors and Expectations – 89
    • Cobitolimod Top Competitors – 90
    • Cobitolimod Expectations – 91
Contact – 92

Complete the form below for a sample of this research.

Name
Newsletter signup